May 13, 2020 / 9:03 PM / 2 months ago

BRIEF-Akero Therapeutics Reports Q1 Loss Per Share Of $0.42

May 13 (Reuters) - Akero Therapeutics Inc:

* AKERO THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* AKERO THERAPEUTICS INC QTRLY LOSS PER SHARE $0.42

* AKERO THERAPEUTICS - EXPECTS TO HAVE DRUG PRODUCT AVAILABLE IN Q4 2020 TO SUPPLY PHASE 2B PORTION OF PHASE 2B/3 CLINICAL TRIAL BEGINNING IN H1 2021

* AKERO THERAPEUTICS INC - COMMERCIAL-SCALE MANUFACTURING OF GMP DRUG SUBSTANCE WAS COMPLETED IN APRIL 2020, WITHOUT ANY IMPACT FROM COVID-19

* AKERO THERAPEUTICS INC - EXPECTS LONGER-TERM PHASE 2B/3 CLINICAL TRIAL TO COMMENCE DURING FIRST HALF OF 2021

* AKERO THERAPEUTICS INC - BEGAN SCREENING FOR COHORT C ON MAY 7, 2020 AND EXPECTS TO BEGIN ENROLLMENT IN Q2 OF THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below